- InstantOn purchase
- Full bookAll chapters
- Any devicePC, tablet, phone
- SecureSSL checkout
Antibodies for Treating Cancer: Basics, Development, and Applications
by Springer-Verlag New York, LLC
Lowest price online, guaranteed. One-time payment, no subscription.
Download link emailed instantly after payment, 24/7
Your download link is sent to the email you enter. Double-check it before completing your order.
File issue? We replace it or refund you, no questions asked.
You'll receive a download link by email immediately after checkout.
Send us the book cover via live chat and we'll request it for you. Typical response time: 10 minutes.
What's inside
This book presents a compact overview of the history, evolution and fascinating novel applications of antibodies for the treatment of cancer, leading the reader step by step to the latest advances. Interesting anecdotes, together with self-explanatory and clearly structured figures with a humorous touch, facilitate the reader’s understanding of this complex topic. Clinical cases round out the book, making it a valuable aid for professionals in their everyday practice. The growing importance of the topics covered here was highlighted by the joint award of the 2018 Nobel Prize in Chemistry to Frances H. Arnold (directed evolution of enzymes), George P. Smith (phage display of peptides) and Sir Gregory P. Winter (phage display of antibodies). Furthermore, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. Many of the antibodies that are now being brought to market target precisely these immune checkpoint modulators. The book addresses a broad readership, ranging from professionals and experts in the field to residents and medical students.
About the Author
Melvyn Little received his degree in chemistry and PhD in biochemistry from Bangor University, Wales and subsequently completed a Postdoc at the Max-Planck-Institute for Cell Biology in Wilhelmshaven, Germany. He has served as head of the Research Group “Recombinant Antibodies” at the German Cancer Research Center in Heidelberg and as an External Professor of Biochemistry at Heidelberg University.
In addition, he was a Co-founder and Supervisory Board Member of the biotech firm Affitech in Oslo, Norway, as well as Founder and Management Board Member of the biotech firm Affimed in Heidelberg.
His primary research interest is in the development of dual binding antibodies for recruiting killer immune cells to destroy tumor cells. Currently he is in retirement and a biotechnology consultant.
| Author | Melvyn Little |
| ISBN-13 | 9783030725990 |
| Publisher | Springer-Verlag New York, LLC |
| Publication Date | 05/10/2021 |
From checkout to chapter one in seconds
Check out securely
Pay by card or wallet. Use an email address you can access right now.
Get your link
Your download link arrives by email the moment your payment clears, 24/7.
Read anywhere
Open it on your laptop, tablet or phone. Save it and keep it.
Smarter than paying full price
Authorised by publisher: licensed copy, never pirated.
Less than Amazon Kindle, with our lowest-price guarantee.
Delivered the moment your payment clears, day or night.
Complete edition: every chapter, no missing pages.
Good to know
How do I receive my ebook?
Right after checkout we email you a download link. Check your spam folder if it doesn't arrive within a few minutes.
Which devices can I read it on?
Any computer, tablet or phone. PDF opens in any browser or free reader app.
I entered the wrong email. What now?
Contact us via live chat with your order number and we'll resend the link to the right address.
What if there's a problem with the file?
We'll replace it or refund you within 30 days, no questions asked.